Human antibodies neutralizing diphtheria toxin in vitro and in vivo by Wenzel, Esther Veronika et al.
1Scientific RepoRtS |          (2020) 10:571  | https://doi.org/10.1038/s41598-019-57103-5
www.nature.com/scientificreports
Human antibodies neutralizing 
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Diphtheria is an infectious disease caused by Corynebacterium diphtheriae. the bacterium primarily 
infects the throat and upper airways and the produced diphtheria toxin (Dt), which binds to the 
elongation factor 2 and blocks protein synthesis, can spread through the bloodstream and affect 
organs, such as the heart and kidneys. For more than 125 years, the therapy against diphtheria has 
been based on polyclonal horse sera directed against Dt (diphtheria antitoxin; DAt). Animal sera 
have many disadvantages including serum sickness, batch-to-batch variation in quality and the use 
of animals for production. In this work, 400 human recombinant antibodies were generated against 
DT from two different phage display panning strategies using a human immune library. A panning 
in microtiter plates resulted in 22 unique in vitro neutralizing antibodies and a panning in solution 
combined with a functional neutralization screening resulted in 268 in vitro neutralizing antibodies. 
61 unique antibodies were further characterized as scFv-Fc with 35 produced as fully human IgG1. The 
best in vitro neutralizing antibody showed an estimated relative potency of 454 IU/mg and minimal 
effective dose 50% (MED50%) of 3.0 pM at a constant amount of DT (4x minimal cytopathic dose) in the 
IgG format. The targeted domains of the 35 antibodies were analyzed by immunoblot and by epitope 
mapping using phage display. All three Dt domains (enzymatic domain, translocation domain and 
receptor binding domain) are targets for neutralizing antibodies. When toxin neutralization assays were 
performed at higher toxin dose levels, the neutralizing capacity of individual antibodies was markedly 
reduced but this was largely compensated for by using two or more antibodies in combination, resulting 
in a potency of 79.4 IU/mg in the in vivo intradermal challenge assay. these recombinant antibody 
combinations are candidates for further clinical and regulatory development to replace equine DAt.
Diphtheria is an infectious disease and caused by Corynebacterium diphtheriae. The bacterium primarily infects 
the throat and upper airways but can also affect other body sites. The produced toxin can spread through the 
bloodstream and affect organs, such as the heart and kidneys. In severe cases, diphtheria toxin (DT) may cause 
myocarditis or peripheral neuropathy. Due to a membrane of dead tissue over the throat and tonsils, swallowing 
and breathing can be difficult. The disease is spread through direct physical contact or by coughing or sneezing 
of infected individuals1–3. Diphtheria is fatal in 5–10% of cases, but children under the age of five have a mortality 
rate of up to 20%. Treatment involves antibiotics to kill the bacteria (erythromycin or penicillin for 14 days) and 
administering of diphtheria antitoxin (DAT) to neutralize the effects of the toxin4–6. C. diphtheriae was identified 
as the causative agent of diphtheria in 1883 and in 1888 the diphtheria toxin was first described in the culture 
medium of C. diphtheriae7. The gene for DT is encoded on a corynebacteriophage8,9 and the toxin is secreted 
as a single polypeptide chain of 535 amino acid residues with a molecular weight of 58 kDa10,11. Mild trypsini-
zation and reduction of DT in vitro generates two fragments, A and B, which remain covalently attached by an 
inter-chain disulfide bond12. Fragment A contains the enzymatic activity, whereas fragment B binds the protein to 
the cell surface receptors and promotes translocation of fragment A to the cytoplasm13,14. DT is composed of three 
structural domains: the catalytic domain (C) corresponds to fragment A (21 kDa) while the transmembrane (T) 
domain (20 kDa) and receptor binding (R) domain (17 kDa) comprise fragment B (37 kDa) (Fig. 1)15. Diphtheria 
toxin binds with the receptor binding domain to heparin-binding epidermal growth factor (HB-EGF) on the cell 
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surface of susceptible cells. This binding triggers receptor-mediated endocytosis of the toxin and the acidic con-
ditions in the endosome lead to a conformational change and the translocation domain of DT to form a channel 
through the endosomal membrane to transport the C-domain to the cytosol16–18. In the cytosol, the C-domain 
catalyzes the NAD+ -dependent ADP-ribosylation of elongation factor 2 (EF-2) of the ribosome resulting in an 
inactivation of the protein synthesis and cell death by apoptosis19,20.
In 1890, Emil von Behring and Shibasaburō Kitasato found that the serum of immunized animals is protective 
against DT21. This serum therapy was a breakthrough for the treatment of diphtheria, especially for children, 
and was awarded with the first Nobel Prize for medicine in 1901. Despite the introduction of effective vaccina-
tion programmes against diphtheria, gaps in immunization coverage still exist, meaning that diphtheria remains 
endemic in some areas. Even in populations with good immunization coverage, isolated cases still occur. In 
recent years, significant diphtheria outbreaks have occurred in countries or regions with a collapsed health system 
because of political instability or civil war, e.g. Yemen, Venezuela or the Rohingya refugee camps in Cox’s Bazar 
(Bangladesh), resulting in failed vaccinations of children22–25. In all clinical cases, the primary therapeutic option 
is still treatment with diphtheria antitoxin (DAT) produced by hyper-immunization of horses.
Production of therapeutic antibodies in horses raises ethical issues surrounding the use of animals, especially 
by substandard housing and veterinary care of the horses, and there are strict requirements for ensuring freedom 
from adventitious agents. Equine hyperimmune sera contain a large and varied amount of different antibodies 
with unknown specificity and, because of the nature of the product, there is potential for variations in quality 
between different batches. The human immune system may develop antibodies against foreign antigens intro-
duced from administration of the animal sera, which leads to the formation of immune complexes, which can 
precipitate in joints or small vessels, activating the complement cascade and initiating a systematic and potentially 
serious inflammatory response, a condition known as serum sickness26–28. Today, DAT is in scarce supply and fre-
quently unavailable to patients because of discontinued production in several countries29. There is an urgent need 
for an alternative to replace the equine DAT, therefore, new treatment options with recombinant fully human 
antibodies are desirable. Recombinant human antibodies are sequence defined, produced in cell culture and as 
they are human proteins, serum sickness can be avoided. These advantages of recombinant antibodies make them 
ideal therapeutics against pathogens and toxins30,31.
The most common technology to generate recombinant human therapeutic antibodies is antibody phage dis-
play32. Antibody phage display allows the selection of antibody fragments, mainly single chain fragment variable 
(scFv) or fragment antigen binding (Fab), directly from human antibody gene libraries in vitro. In brief, antibody 
fragments are displayed on the surface of filamentous M13 phage particles by linking the antibody to the phage 
protein III. The corresponding antibody gene fragment is encoded on a phagemid packaged in the phage particles 
so that, phenotype and genotype are coupled. In a selection process called “panning”, antibody phage particles 
are incubated with the antigen, non-binding phage particles are washed away and the binding antibody phage 
particles are eluted. This process is repeated 2–3 times. Subsequently, monoclonal antibodies are produced and 
screened for antigen binding, e.g. ELISA on antigen, or in functional assays, e.g. neutralization assays33–36. Because 
the gene encoding the antibody fragment is directly accessible, the antibodies can be converted into other anti-
body formats such as scFv-Fc or IgG, for further experiments and applications37,38. Antibody phage display is a 
Figure 1. Protein structure of diphtheria toxin: C-domain (red), T-domain (blue), R-domain (green) (modified 
from PhD thesis84). A) crystal structure, the catalytic center is marked in cyan and the amino acids binding the 
HB-EGF receptor are marked brown (modified from pdb 1ddt85). B) Schematic structure of DT.
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well validated tool to generate recombinant antibodies against toxins for diagnostic and therapeutic purposes39–44. 
An overview of antibodies generated by phage display against pathogens and toxins is given by Kuhn et al.31. 
An overview on phage display derived therapeutic antibodies is given by Frenzel et al.32.
In this work, recombinant human antibodies against DT were generated using phage display to neutralize 
DT in vitro and in vivo and to identify potential future alternatives to equine DAT as a frontline therapy for 
diphtheria.
Results
immune antibody library construction. Three individuals received a regular booster immunization with 
an adsorbed diphtheria and tetanus vaccine. Seven days after immunization, EDTA-treated blood samples were 
collected and PBMCs extracted with Ficoll. An average concentration of 4.7 × 107 PBMC/mL was counted. Two 
immune antibody gene libraries were constructed. For the first library, the total PBMCs were used and the RNA 
was isolated resulting in 10.5 µg total RNA used for cDNA synthesis. The cDNAs derived from the blood of each 
person was kept separated in the construction process of the total PBMC library and the final sublibraries were 
combined. This first immune library was called VJN library. For the second library, the freshly prepared PBMCs 
were stained with a florescence conjugated CD138+ antibody to detect the antibody-producing B cells. In the next 
step, the stained cells were selected by fluorescence activated cell sorting (FACS). 8.8 × 107 PBMCs were sorted, 
resulting in the isolation of 2,501 CD138+ cells ( = 0.003%). Their RNA was extracted (350 ng total RNA) and 
transcribed in cDNA. This second immune library was called the CD138+ library.
The cDNA from total PBMC and CD138+ sorted cells was used to amplify the gene sequences of the var-
iable regions of immunoglobulin heavy and light chains (VH and VL). The VH and VL were cloned into the 
phage display vector pHAL51. Separate lambda and lappa libraries were constructed. The maximal diversity of the 
sub-libraries, as determined by the number of independent clones, was between 1.3–3.4 × 108, with an insert rate 
of 73–95%. Subsequently, the libraries were packaged with Hyperphage45,46 to display the scFv antibody coupled 
to the pIII on the phage. For packaging, the sub-libraries of the total PBMC approach were pooled resulting in 
the VJN library. The lambda and kappa libraries were still kept separate. This resulted in phage titers of 7.4 × 1012 
cfu/mL for VJN lambda library, 7.2 × 1012 cfu/mL for VJN kappa library, 2.6 × 1012 cfu/mL for CD138+ lambda 
library and 6.0 × 1012 cfu/mL for CD138+ kappa library.
Selection and screening of anti-diphtheria toxin antibodies. For antibody selection, both VJN and 
CD138+ immune libraries were used. Two different panning and screening strategies were chosen for antibody 
selection. In the first approach, the antigen was immobilized on a microtiter plate (MTP) and the screening was 
performed by ELISA of secreted soluble scFv fragments to determine antigen binding. In the second strategy, a 
panning in solution was performed using biotinylated antigen followed by a functional screening of DT neutrali-
zation using the Vero cell assay. Using both approaches, 400 antibodies binding to DAT were selected in total. The 
overview showing all panning strategies and the subsequent steps is given in Table 1.
Using the first strategy relying on antigen immobilization on MTPs, 132 scFvs were isolated in total from 
both immune libraries. For the analysis of the individual antibody sequence, a BstNI digestion and agarose gel 
electrophoresis was initially performed to exclude duplicate clones which have identical digestion patterns (data 
not shown), followed by sequencing of the scFv encoding gene inserts. 101 of these scFv were identified as unique 
after sequencing. One antibody contained a stop codon in the sixth position of the VH chain (ewe192-B5), despite 
being produced in functional form in E. coli. For this antibody, the respective germline sequence (IGHV4-34*01) 
encodes the amino acid glutamine (Q) at position 6. After polymerase incomplete primer extension (PIPE) clon-
ing, the stop codon was changed to the amino acid Q. This modified antibody was labelled as ewe192-B5(P). For 
all further characterizations, the scFv antibodies against DT were converted to an IgG-like scFv-Fc format. The 
genes encoding scFv antibody fragments were cloned into the pCSE2.7-hIgG1-Fc expression vector and produced 
as scFv-Fc.
Library type Light chain type
Panning 
strategy Screening strategy
Antibody 
selection 
campaign
Selected 
mabs
Produced 
& purified 
as scFv-Fc
Binding 
in ELISA 
as scFv-Fc
Neutra-
lizing as 
scFv-Fc
Produced 
& purified 
as IgG
Binding 
in ELISA 
as IgG
Neutra-
lizing 
as IgG
Immune Lambda+ Kappa (mix) MTP scFv binding ewe191 67 51/67 35/51 10/35 10/10 10/10 9/10
Immune (CD138+ 
selected) Lambda+ Kappa (mix) MTP scFv binding ewe192 65 50/65 38/50 12/38 12/12 12/12 12/12
Immune Lambda in solution scFv-Fc neutralization ewe371 71 13/71 13/13 13/13 1/13 1/1 1/1
Immune Kappa in solution scFv-Fc neutralization ewe372 66 15/66 18*/15 18/18 10/15 10/10 10/10
Immune (CD138+ 
selected) Lambda in solution scFv-Fc neutralization ewe374 54 3/54 3/3 3/3 0/3 — —
Immune (CD138+ 
selected) Kappa in solution scFv-Fc neutralization ewe375 77 5/77 5/5 5/5 2/5 2/2 2/2
Sum 400 137 112 61 35 35 34
Table 1. Overview of all selected antibodies separated by library type, light chain type, panning strategy, 
screening strategy and further production and characterization steps. *Three of the 15 antibodies were 
produced in two variants: (1) original phage display selected sequence and (2) modified framework 1 sequence 
according to the corresponding V-gene germline sequence. This data was generated in a PhD thesis84.
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In the second strategy using panning in solution, a pull down was performed using magnetic streptavidin 
beads to capture the antibody phage bound to the biotinylated DT in solution. The successful enrichment of 
DT-binding phage by panning in solution was followed by a phage ELISA (data not shown). The antibody pool 
was directly cloned into the vector pCSE2.7-hIgG1-Fc-XP for production as scFv-Fc fusions. 384 monoclonal 
scFv-Fc were selected for the screening assay. All antibodies were produced in EXPI293F cells in 96 deep well 
plates. The produced antibodies were secreted into the growth medium and the supernatant was used for per-
forming the neutralization assay in Vero cells. A four-point serial dilution of the supernatant was incubated with 
a constant amount of diphtheria toxin (4 × minimal cytopathic dose, 4 × MCD) and, after 6 days of incubation 
with Vero cells, the cytopathic effect was measured with an Thiazolyl Blue Tetrazolium Bromide (MTT) assay. 
These produced antibodies were analyzed regarding their neutralization efficacy using the Vero cell TNT assay47 
(data not shown). In total, 268 scFv-Fc showed neutralization. The 36 antibodies showing the best neutralization 
were selected for further analysis.
Three antibodies (ewe372-C10, ewe372-D3 and ewe372-H1) contained a stop codon in the sixth position of 
the VH chain. For these three antibodies, the corresponding germline gene (IGHV4-34) encodes the amino acid 
glutamine (Q) at position six. A point mutation was introduced to change the stop codon to the amino acid Q. 
These three antibodies had the amino acid Serin (S) at position 7 of VH, but according to the corresponding germ 
line gene, the amino acid tryptophan (W) should occur at this position. Hence, two versions were developed for 
each of the three antibodies and named after their seventh amino acid position ewe372-C10-S/ewe372-C10-W, 
ewe372-D3-S/ewe372-D3-W and ewe372-H1-S/ewe372-H1-W. After these modifications, a total of 39 scFv-Fc 
antibodies from the panning in solution were further analyzed.
In vitro neutralization in scfv-fc format. The in vitro neutralization capacity of the 101 unique scFv-Fc 
derived from the panning in MTPs, and the 39 best neutralizing scFv-Fc derived from the panning in solution, 
were further analyzed to determine the minimal effective dose 50% (MED50%) (lowest antibody concentration 
with more than 50% neutralization efficacy) using the Vero cell TNT assay47. Here, a serial dilution of purified 
scFv-Fc was incubated with a constant amount of DT (4 × MCD) and the cytopathic effect was measured with 
an MTT assay. 22 of the 101 scFv-Fc derived from the panning in MTPs showed DT neutralization (Fig. 2). The 
neutralization capacity of the scFv-Fc derived from the panning in solution are shown in Fig. 3. The in vitro 
neutralization capacity was determined to be between 3.3 pM (3.7 × 10−7 mg/mL) and 18.8 µM (2 mg/mL) at a 
constant amount of DT (4 × MCD) (Table 2). Most of the scFv-Fc had a neutralization efficacy in the nanomolar 
range. The antibody germline V-genes of all 61 neutralizing antibodies are given in Table 3.
Figure 2. Cell based neutralization assay (using a DT dose level of 4 × MCD) for 21 scFv-Fc derived from the 
panning in MTPs. The OD for untreated (control) Vero cells is shown as a horizontal green dotted line. The 
threshold for neutralization (defined as 50% of the control cell OD) is shown as a horizontal red dotted line. The 
antibody ewe192-B5(P) (green, open symbol and dotted line) was used as positive control and to standardize 
the assays performed in parallel on different MTPs. Figure modified from PhD thesis84.
5Scientific RepoRtS |          (2020) 10:571  | https://doi.org/10.1038/s41598-019-57103-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
Dt binding in scfv-fc format determined by titration eLiSA. The half maximal effective concentra-
tion (EC50) was determined for the selected 61 neutralizing scFv-Fc antibodies by performing a titration ELISA 
on immobilized DT and the non-toxic mutant of DT, CRM197 which contains a point mutation in the catalytic 
domain48,49 (Fig. 4 and Table 2). The EC50 for DT ranged widely from 0.0086 µg/mL to 11.9 µg/mL. The non-toxic 
mutant CRM197 showed binding in the range of 0.0108 µg/mL to 18.4 µg/mL. Out of 61 scFv-Fc antibodies, 16 
showed more than 3-fold decreased binding to the non-toxic DT-mutant CRM197 compared to DT.
DT binding in IgG format determined by titration ELISA.  38 neutralizing scFv-Fc antibodies were 
cloned into the pCSEH1c (heavy chain) and pCSL3l/pCSL3k (light chain lambda/kappa) vectors37 for produc-
tion as human IgG1. The antibodies were chosen because of their neutralization efficacy as scFv-Fc but from 
antibodies which very similar CDRs only one representing antibody was chosen. Three of the antibodies were 
not producible in IgG format (ewe372-C10-S, ewe372-F3 and ewe374-F7). The remaining 35 IgG were titrated 
by ELISA against DT and CRM197 (Fig. 5). All IgG antibodies bound DT, but some antibodies showed a reduced 
affinity binding the non-toxic mutant CRM197. The EC50 ranged from 0.0182 µg/mL to 0.523 µg/mL for DT and 
from 0.0214 µg/mL to 40.08 µg/mL for CRM197 (Table 2). Out of 35 IgG antibodies, 8 showed more than 3-fold 
Figure 3. Cell based neutralization assay for 39 scFv-Fc antibodies derived from the panning in solution. 
Untreated Vero cells are given as green dotted line. The threshold for neutralization is given as red dotted line 
(50% of untreated Vero cells). The anti-glucan antibody JoJ58B9 (red, open symbols and dotted line) is the 
negative control and the antibody ewe192-B5(P) (green, open symbol and dotted line) is the positive control. 
Antibodies represented in coloured symbols were further analysed and antibodies represented in grey symbols 
were excluded. Figure modified from PhD thesis84.
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#
Name antibody 
clone
DT binding in vitro neutralization
EC50 (µg/mL) 
scFv-Fc
CRM197 EC50 (µg/mL)
scFv-Fc
EC50  
(µg/mL) IgG
CRM197 EC50 
(µg/mL) IgG
MED50% (nM)
scFv-Fc MED50% (nM) IgG IU/mg 
IgG(nM) (mg/mL) (nM) (mg/mL)
1 ewe191-A7 0.0086 0.0108 0.0244 0.0245 18854.3 2.07397 140.3 0.02034 0.0049
2 ewe191-A9 0.0154 2.8240 0.0264 1.4110 1266.1 0.13927 1098.5 0.15928 0.0013
3 ewe191-C1 0.0101 0.0218 0.0381 0.0311 2360.9 0.25969 818.5 0.11868 0.0017
4 ewe191-C10 0.1748 1.5410 0.3541 1.0200 1821.7 0.20038 n.d. n.d. —
5 ewe191-C11 0.0105 0.0122 0.0253 0.0312 7.6 0.00083 0.6 8.7E-05 2.2
6 ewe191-C12 0.0254 0.0200 0.0466 0.0468 7.3 0.00080 2.4 0.000348 0.57
7 ewe191-D1 0.0100 0.0125 0.0266 0.0310 36.9 0.00406 31.2 0.00452 0.044
8 ewe191-E12 0.0459 0.0246 0.0297 0.0329 43.2 0.00475 19.2 0.00278 0.071
9 ewe191-H10 0.0335 0.0839 0.0285 0.0332 65.4 0.00719 119.1 0.01727 0.017
10 ewe191-H8 0.0143 0.0251 0.0578 0.0931 3.9 0.00043 1.0 0.000145 1.45
11 ewe192-A6 0.2031 0.6579 0.4095 40.0800 500.8 0.05509 780.7 0.1132 0.0018
12 ewe192-B5(P) 0.0441 0.0587 0.0535 0.0679 0.075 8.25E-06 0.007 1.02E-06 124
13 ewe192-C11 0.0113 0.0227 0.0337 0.0312 313.8 0.03452 116.7 0.01692 0.012
14 ewe192-D7 0.0119 0.0133 0.0333 0.0291 26.4 0.00290 3.4 0.000493 0.41
15 ewe192-D8 3.9280 3.3680 0.3612 2.4640 4667.8 0.51346 949.3 0.13765 0.0015
16 ewe192-E4 0.0920 0.2222 0.0681 30.9200 301.3 0.03314 35.7 0.00518 0.039
17 ewe192-F11 0.49 2.0760 0.2021 31.6400 1312.7 0.1444 1415.9 0.20531 0.0010
18 ewe192-F6 0.1558 0.5040 0.1380 7.5480 287.9 0.03167 357.6 0.05185 0.0038
19 ewe192-G12 0.89 1.4080 0.5226 34.1600 2911.9 0.32031 180.8 0.02622 0.0076
20 ewe192-H11 0.0143 0.1678 0.0263 0.0453 5506.8 0.60575 1351.3 0.19594 0.0010
21 ewe192-H7 0.0138 0.0144 0.0349 0.0245 18.8 0.00207 10.9 0.00158 0.14
22 ewe192-H8 0.1589 0.3111 0.0938 3.5430 303.6 0.0334 254.0 0.03683 0.0054
23 ewe371-A2 0.08299 0.1176 n.d. n.d. 77.272 0.0085 n.d. n.d. n.d.
24 ewe371-A6 0.03316 0.04078 n.d. n.d. 20.324 0.002236 n.d. n.d. n.d.
25 ewe371-B12 0.01456 0.0141 0.0182 0.0214 1.407 0.000155 1.2028 0.000174 1.15
26 ewe371-D10 0.02058 0.02136 n.d. n.d. 5.496 0.000605 n.d. n.d. n.d.
27 ewe371-D4 0.02356 0.02439 n.d. n.d. 0.642 7.06E-05 n.d. n.d. n.d.
28 ewe371-D7 0.02815 0.03871 n.d. n.d. 10.621 0.001169 n.d. n.d. n.d.
29 ewe371-E4 0.03578 0.1132 n.d. n.d. 16.373 0.0018 n.d. n.d. n.d.
30 ewe371-E7 0.02544 0.03123 n.d. n.d. 10.134 0.001114 n.d. n.d. n.d.
31 ewe371-G2 0.02945 0.04119 n.d. n.d. 1.107 0.000121 n.d. n.d. n.d.
32 ewe371-G4 0.2942 4.738 n.d. n.d. 0.622 6.842E-05 n.d. n.d. n.d.
33 ewe371-G8 0.03405 0.04117 n.d. n.d. 9.841 0.001082 n.d. n.d. n.d.
34 ewe371-H1 0.02254 0.06175 n.d. n.d. 24.006 0.00264 n.d. n.d. n.d.
35 ewe371-H9 0.03138 0.04574 n.d. n.d. 1.419 0.000156 n.d. n.d. n.d.
36 ewe372-A12 0.02153 0.03627 0.0210 0.0291 8.032 0.000883 4.1944 0.000608 0.33
37 ewe372-A8 0.02257 0.02301 0.0239 0.0279 0.0512 5.63E-06 0.0826 1.2E-05 16.6
38 ewe372-C10-S 0.05643 0.2061 n.d. n.d. 0.00483 5.31E-07 n.d. n.d. n.d.
39 ewe372-C10-W 0.04717 0.1936 0.0356 0.0548 0.00551 6.06E-07 0.0057 8.27E-07 240.70
40 ewe372-C4 0.03015 0.03387 0.0323 0.0381 0.03261 3.59E-06 0.0297 4.31E-06 46.51
41 ewe372-C5 0.03221 0.03299 0.0344 0.0398 0.01906 2.1E-06 0.0133 1.93E-06 103.98
42 ewe372-C8 0.03915 0.04011 n.d. n.d. 0.140 1.54E-05 n.d. n.d. n.d.
43 ewe372-D11 0.02329 0.03616 0.0243 0.0311 2.231 0.000245 1.6808 0.000244 0.82
44 ewe372-D12 0.04246 0.04771 n.d. n.d. 0.723 7.95E-05 n.d. n.d. n.d.
45 ewe372-D3-S 0.05643 0.2061 n.d. n.d. 128.760 0.01416 n.d. n.d. n.d.
46 ewe372-D3-W 0.04717 0.1936 n.d. n.d. 63.490 0.00698 n.d. n.d. n.d.
47 ewe372-D7 0.03223 0.0365 0.0286 0.0329 0.01039 1.14E-06 0.0062 8.99E-07 220.7
48 ewe372-D9 0.08502 0.2127 n.d. n.d. 1.470 0.00016 n.d. n.d. n.d.
49 ewe372-F3 0.03983 0.05432 n.d. n.d. 0.00339 3.73E-07 n.d. n.d. n.d.
50 ewe372-F6 0.01995 0.0313 0.0264 0.0284 2.011 0.000221 0.6098 8.84E-05 2.24
51 ewe372-G2 0.02719 0.03091 n.d. n.d. 2.236 0.000245 n.d. n.d. n.d.
52 ewe372-H1-S 0.0382 0.1002 0.0282 0.0467 0.00515 5.67E-07 0.0057 8.26E-07 239.7
53 ewe372-H1-W 0.0364 0.09968 0.0283 0.0416 0.00508 5.59E-07 0.0030 4.35E-07 454.4
54 ewe374-C9 0.1311 2.049 n.d. n.d. 4.238 0.000466 n.d. n.d. n.d.
Continued
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decreased binding to CRM197 compared to DT. DT binding by IgG differed from the corresponding scFv-Fc 
significantly only for a few antibodies. One IgG gained more than 3-fold EC50 (ewe192-D8) compared to the 
scFv-Fc format and two antibodies lost 3-fold EC50.
In vitro neutralization in IgG format.  The 35 IgG antibodies were tested for their ability to neutralize 
DT in the Vero cell TNT assay47 (Fig. 6). The MED50% of all purified IgG antibodies was between 3.0 pM and 
1.4 µM at a constant amount of DT (4x MCD) (Table 2). Only one antibody (ewe191-C10) lost complete neutral-
ization capacity after conversion to the IgG format. Interestingly, 11 IgG had at least a 3-fold enhancement of the 
MED50% compared to the corresponding scFv-Fc. The antibody ewe191-A7 showed a more than 100x improved 
MED50% but the initial in vitro neutralization efficacy of this antibody was low. The MED50% did not change 
more than 3-fold for the antibodies with a high neutralization efficacy except for ewe192-B5(P) which showed a 
10-fold improvement.
Neutralizing potency was expressed in International Units (IU) per mg by comparison with the WHO 
International Standard for Diphtheria Antitoxin, Equine (NIBSC code 17/230). The results are summarized in 
Fig. 7. The monoclonal antibodies showed a neutralization potency up to 455 IU/mg (Table 2). By comparison, 
a rat hybridoma antibody (DT05) and the corresponding recombinant version (rDT05) had a neutralization 
potency of 46.4 IU/mg and 36.6, IU/mg respectively. The neutralizing potency of a batch of equine DAT was also 
determined and, although not directly comparable, the specific activity was estimated to be approximately 50 
IU/mg (based on total protein concentration of the purified antiserum). As an additional experiment, the best 
neutralizing antibodies were combined, but no synergistic effect was observed in the Vero cell assay using a DT 
dose of 4 × MCD (data not shown).
Domain mapping. To identify the individual domain targeted by the 35 antibodies, the A- and B-fragments, 
as well as the receptor binding (R) and translocation (T) domains alone, were produced in E. coli as recombi-
nant proteins. Binding to the A- and B-fragments was first tested in scFv-Fc format by immunoblot (data not 
shown). For antibodies that were shown to bind the B-fragment, the antibody was further tested also on the R- 
and T-domains. The results are given in Table 4.
According to the domain mapping by immunoblot, 10 antibodies bound the R domain, 15 antibodies 
bound the C-domain and 1 antibody bound the T-domain. 4 antibodies bound the B-fragment, but did not 
bind separately to either the T- or R-domain alone, and for 4 antibodies it was not possible to determine the 
domain. These results showed that the majority of neutralizing antibodies were targeting the R domain. The 
best neutralizing antibodies against the R-domain were ewe375-D4 and ewe372-C10-W, the best IgG against 
the C-domain was ewe375-H4, and the best neutralizing antibody binding the T-domain was ewe372-F6. The 
antibody ewe372-C10-W was excluded from further analysis because the size exclusion chromatography (SEC) 
profile showed an increased formation of dimers (data not shown).
epitope mapping using single gene phage display. To identify the epitopes, the DNA for the 
B-fragment and the sequence encoding the C- and T-domains were fragmented and two independent phage 
display libraries were constructed by cloning into the ORFeome phage display vector pHORF350 followed by 
packaging with Hyperphage for ORF selection to improve library quality. The library quality and the coverage of 
the complete DT gene was analyzed by sequencing of approximately 80 clones (Supplementary Fig. 1) showing a 
nearly complete coverage of DT using this limited amount of sequences. We expected to get also overlapping C-T 
fragments and were surprised to get the most fragments at the beginning of the C or T domain. Subsequently, 
a panning was performed on 34 of the 35 best neutralizing antibodies in the scFv-Fc format using the A- and 
the B-fragment libraries separately. We excluded ewe191-C10 because this antibody lost neutralization capac-
ity after conversion to the IgG format. Individual epitope phage clones from the second panning round were 
screened by ELISA. For 19 antibodies, the minimal epitope region (MER) was identified (Table 4). An overview 
of all identified MERs is given in Fig. 8 and the detailed sequencing results for each identified MER are given 
in Supplementary Fig. 2A–S. For two antibodies no binding partners were identified in the screening ELISA. 
#
Name antibody 
clone
DT binding in vitro neutralization
EC50 (µg/mL) 
scFv-Fc
CRM197 EC50 (µg/mL)
scFv-Fc
EC50  
(µg/mL) IgG
CRM197 EC50 
(µg/mL) IgG
MED50% (nM)
scFv-Fc MED50% (nM) IgG IU/mg 
IgG(nM) (mg/mL) (nM) (mg/mL)
55 ewe374-E6 0.3193 2.255 n.d. n.d. 7.6778 0.000844 n.d. n.d. n.d.
56 ewe374-F7 0.01272 0.01367 n.d. n.d. 7.641 0.000840 n.d. n.d. n.d.
57 ewe375-B8 0.1135 0.2739 n.d. n.d. 0.946 0.000104 n.d. n.d. n.d.
58 ewe375-D2 0.03781 18.38 n.d. n.d. 151.6152 0.016678 n.d. n.d. n.d.
59 ewe375-D4 0.04593 0.06574 0.0274 0.0362 0.00619 6.81E-07 0.0031 4.5E-07 446.3
60 ewe375-G7 11.9 3.429 n.d. n.d. 20.020 0.002202 n.d. n.d. n.d.
61 ewe375-H4 0.03662 0.1174 0.0220 0.0343 0.114 1.25E-05 0.0669 9.7E-06 20.4
Table 2. Overview of the half maximal binding concentration (EC50) in the scFv-Fc and IgG format on DT 
and CRM197 in ELISA. The in vitro neutralization capacity in the Vero cell TNT assay (using a toxin dose of 
4 × MCD) is shown as MED50% (for scFv-Fc and IgG) and IU/mg (for IgG only). n.d. = not done. For the 
conversion of nM to mg/mL a mean molecular weight of 110 kD for scFv-Fc and 145 kD for IgG was used. This 
data was generated in a PhD thesis84.
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#
Name 
antibody clone
VH VL
V D J V J
1 ewe191-A7 IGHV3-33*01 IGHD6-13*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01
2 ewe191-A9 IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*01
3 ewe191-C1 IGHV1-3*01 IGHD3-10*01 IGHJ6*02 IGKV3-15*01 IGKJ4*01
4 ewe191-C10 IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGLV3-21*02 IGLJ3*01
5 ewe191-C11 IGHV3-33*01 IGHD6-13*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01
6 ewe191-C12 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ3*01
7 ewe191-D1 IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGLV1-47*02 IGLJ3*01
8 ewe191-E12 IGHV5-51*01 IGHD3-16*01 IGHJ5*02 IGLV1-44*01 IGLJ1*01
9 ewe191-H10 IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGLV3-21*02 IGLJ3*02
10 ewe191-H8 IGHV3-23*04 IGHD3-10*01 IGHJ4*02 IGLV1-44*01 IGLJ3*02
11 ewe192-A6 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ5*01
12 ewe192-B5(P) IGHV4-34*01 IGHD4-17*01 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
13 ewe192-C11 IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV8-61*01 IGLJ3*01
14 ewe192-D7 IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV2-23*03 IGLJ3*02
15 ewe192-D8 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGLV3-21*02 IGLJ3*02
16 ewe192-E4 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ4*01
17 ewe192-F11 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGLV1-40*01 IGLJ3*01
18 ewe192-F6 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ1*01
19 ewe192-G12 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ3*01
20 ewe192-H11 IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-11*01 IGLJ3*02
21 ewe192-H7 IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-23*03 IGLJ3*02
22 ewe192-H8 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3D-15*01 IGKJ5*01
23 ewe371-A2 IGHV3-33*01 IGHD2-2*01inv IGHJ3*02 IGLV2-14*04 IGLJ3*01
24 ewe371-A6 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV3-21*01 IGLJ3*01
25 ewe371-B12 IGHV3-33*01 IGHD6-13*01 IGHJ4*03 IGLV1-47*01 IGLJ3*01
26 ewe371-D10 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ3*02
27 ewe371-D4 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV3-19*01 IGLJ3*01
28 ewe371-D7 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ3*01
29 ewe371-E4 IGHV3-23*01 IGHD3-10*01 IGHJ4*02 IGLV2-14*04 IGLJ1*01
30 ewe371-E7 IGHV5-51*01 IGHD2-2*01 IGHJ5*02 IGLV2-8*01 IGLJ3*01
31 ewe371-G2 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ1*01
32 ewe371-G4 IGHV4-34*01 IGHD5-12*01 IGHJ6*02 IGLV1-44*01 IGLJ3*02
33 ewe371-G8 IGHV1-3*01 IGHD2-2*01 IGHJ6*02 IGLV1-44*01 IGLJ3*02
34 ewe371-H1 IGHV3-23*04 IGHD3-10*01 IGHJ4*02 IGLV1-44*01 IGLJ3*01
35 ewe371-H9 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ3*02
36 ewe372-A12 IGHV1-3*01 IGHD6-19*01 IGHJ3*01 IGKV1-27*01 IGKJ4*01
37 ewe372-A8 IGHV1-69*04 IGHD6-13*01 IGHJ3*02 IGKV1D-39*01 IGKJ3*01
38 ewe372-C10-S IGHV4-34*01 IGHD2-2*02 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
39 ewe372-C10-W IGHV4-34*01 IGHD2-2*02 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
40 ewe372-C4 IGHV1-69*04 IGHD1-1*01 IGHJ4*02 IGKV1D-39*01 IGKJ4*01
41 ewe372-C5 IGHV1-69*04 IGHD2-2*02 IGHJ4*02 IGKV1D-39*01 IGKJ4*01
42 ewe372-C8 IGHV1-69*04 IGHD2-2*02 IGHJ4*02 IGKV1D-39*01 IGKJ4*01
43 ewe372-D11 IGHV1-18*01 IGHD3-10*01 IGHJ6*02 IGKV3-20*01 IGKJ4*01
44 ewe372-D12 IGHV1-69*04 IGHD2-2*02inv IGHJ4*02 IGKV1D-39*01 IGKJ4*01
45 ewe372-D3-S IGHV4-34*02 IGHD2-15*01 IGHJ4*02 IGKV3-15*01 IGKJ1*01
46 ewe372-D3-W IGHV4-34*02 IGHD2-15*01 IGHJ4*02 IGKV3-15*01 IGKJ1*01
47 ewe372-D7 IGHV1-69*04 IGHD2-21*02 IGHJ4*02 IGKV1D-39*01 IGKJ4*01
48 ewe372-D9 IGHV1-46*03 IGHD1-20*01 IGHJ4*02 IGKV1D-33*01 IGKJ5*01
49 ewe372-F3 IGHV1-46*03 IGHD1-20*01 IGHJ4*02 IGKV1-12*02 IGKJ4*01
50 ewe372-F6 IGHV3-23*04 IGHD4-17*01inv IGHJ6*02 IGKV1-5*03 IGKJ5*01
51 ewe372-G2 IGHV1-69*06 IGHD2-15*01 IGHJ4*02 IGKV1D-39*01 IGKJ4*01
52 ewe372-H1-S IGHV4-34*02 IGHD4-17*01 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
53 ewe372-H1-W IGHV4-34*02 IGHD4-17*01 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
54 ewe374-C9 IGHV4-34*01 IGHD5-12*01 IGHJ6*02 IGLV1-44*01 IGLJ3*01
55 ewe374-E6 IGHV4-34*01 IGHD5-18*01 IGHJ6*02 IGLV3-19*01 IGLJ1*01
56 ewe374-F7 IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-23*03 IGLJ3*02
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For 13 antibodies the data were inconclusive because DT fragments of two epitope regions were selected and 
identified in the screening ELISA (e.g. for ewe192-F11 in Supplementary Fig. 2T), or clones from one epitope 
region were identified but, in addition, more than one outlier in other DT regions or inverse clones were selected. 
For ewe372-H1-S, the outlier may be excluded because of the results derived from ewe372-H1-W which differs 
only by one amino acid in framework one. The length of the identified MERs ranged from 14 amino acids for 
ewe192-D8 to the complete C-domain for ewe372-D11 ewe374-H4. The domains identified using the immunob-
lot approach were always in accordance with the domains identified by epitope mapping.
The combined results of the immunoblot and the phage display approach suggest that 15 antibodies bound the 
C-domain, 11 bound the R-domain, 4 bound the T-domain, and for one antibody no domain was assigned. For 3 
antibodies, only the complete B fragment was identified using both approaches.
Affinity determination.  Six anti-DT antibodies in the scFv-Fc and IgG format were further characterized 
by Microscale Thermophoresis (MST) measurements to determine their EC50 value in solution. Here, we focused 
on the antibodies ewe191-A7 and ewe191-C12 as well as ewe192-B5(P) as the best neutralizing antibodies derived 
from MTP panning. Furthermore, all three antibodies derived from panning in solution (ewe372-F6, ewe375-D4 
and ewe375-H4) that were later tested in guinea pig in vivo protection assays were included in this analysis. The 
results are given in Table 5 and Supplementary Figure 3. The EC50 values of the antibodies in IgG format were 
quite similar, ranging from 9.4 nM to 13.6 nM. In the scFv-Fc format, the measured EC50 values were more 
diverse. For half of the antibodies the EC50 value decreased to 3–7 nM, and for the other half it increased to 
20–40 nM. The observed difference in the formats might be due to the altered flexibility of the antibody arms hav-
ing an influence on the avidity of the antibody. This avidity behavior was also visible in the MST measurement in 
the form of a secondary binding event for ewe191-A7, ewe191-C12, ewe372-F6 and ewe375-H4 in both formats.
In vitro neutralization using higher toxin concentrations and the effect of using antibody com-
binations. The antibodies ewe375-D4, ewe375-H4 and ewe372-F6 selected for in vivo protection experiments 
were further analyzed in the Vero cell TNT assays47 using higher toxin concentrations. These in vitro assays were 
performed at a range of (increasing) DT dose levels referred to as Lcd/1000, Lcd/100 and Lcd/10. The amount of 
toxin needed to cause more than 50% cell death in the presence of a fixed, defined amount of reference DAT is 
given as the limit of cytopathic dose (Lcd). The Lcd number refers to the inverse of the antitoxin concentration 
in IU. Hence, Lcd/1 is the amount of toxin per mL causing >50% cell death in the presence of 1 IU DAT, Lcd/10 
for 0.1 IU DAT, and so forth. In our assay, Lcd/1000 equates to approximately 40 × MCD. In addition, neutral-
ization using 4 × MCD was measured in parallel again for direct comparison. The sensitivity of cells to DT is 
given as multiple of the minimum cytopathic dose (MCD) – so the assay performed at 4 × MCD uses a fixed 
DT concentration that is 4 × higher than the minimum concentration causing >50% cell death. The results for 
individual antibodies and antibody combinations are given in Table 6. The results for the neutralization assay 
using 4 × MCD are, as expected, in the same range as the results given in Table 2. There was no loss of potency 
when using Lcd/1000 (~40 × MCD), but the individual antibodies lost neutralization capacity at higher DT dose 
levels of Lcd/100 or Lcd/10. However, strong neutralizing activity was observed when antibodies were used in a 
combination of two or three, giving a specific activity ranging from 80–160 IU/mg (Table 6).
Analysis of in vivo neutralization by intradermal challenge and the effect of antibody combina-
tions. The in vivo neutralization efficacy of the antibodies was analyzed in a non-lethal intradermal challenge 
assay in guinea pigs using a DT dose of Lr/10051,52. Lr/100 is defined as the smallest amount of DT that causes a 
weak but detectable erythema in the presence of 0.01 IU of reference DAT antitoxin. The Lcd/100 level of DT in 
the in vitro TNT Vero cell assay is analogous to Lr/100 in the in vivo intradermal challenge assay, showing that 
the in vitro assay may be a suitable replacement for the in vivo test. The results are given in Table 7. The individual 
antibodies did not show a high level of neutralization, whereas all antibody pairs and the triple antibody combi-
nation resulted in a neutralization potency of 79 IU/mg.
Discussion
We describe here the development of recombinant human monoclonal antibodies that neutralize DT and have the 
potential to be developed further as a therapeutic alternative to equine DAT. The use of recombinant antibodies 
is the prevailing approach for the development of therapeutic antibodies53–55. The advantages include a sequence 
defined human antibody produced under controlled and reproducible conditions in mammalian cell culture as 
#
Name 
antibody clone
VH VL
V D J V J
57 ewe375-B8 IGHV5-51*01 IGHD1-7*01 IGHJ5*02 IGKV3-20*01 IGKJ3*01
58 ewe375-D2 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ5*01
59 ewe375-D4 IGHV4-34*02 IGHD4-17*01 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
60 ewe375-G7 IGHV1-69*04 IGHD1-26*01 IGHJ4*02 IGKV1D-39*01 IGKJ3*01
61 ewe375-H4 IGHV5-51*01 IGHD1-7*01 IGHJ5*02 IGKV3-20*01 IGKJ3*01
Table 3. Overview of the V-gene distribution for all 61 neutralizing antibodies selected for further analysis. The 
V-gene analysis was performed using VBASE2 (www.vbase2.org)80. This data was generated in a PhD thesis84.
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opposed to an animal derived blood product with batch-to-batch variation and the risk of adverse reaction in the 
form of serum sickness.
Human recombinant antibodies were selected from two different immune libraries derived from immu-
nized donors. The first library was constructed from all PBMCs while the second was derived only from CD138+ 
plasma cells. Two panning approaches were performed using both libraries. Panning on immobilized antigen 
and panning in solution were both performed because the output using both strategies may differ due to differ-
ent ways an antigen is presented, and to mitigate the risk of denaturation by MTP immobilization56. In order to 
improve the throughput, for the clones enriched by panning in solution, a functional screening on DT neutral-
ization was performed to directly identify neutralizing antibodies, instead of identification of binding followed 
by neutralization. The observed V-gene distribution of the DT neutralizing antibodies matched the distribution 
Figure 4. Titration ELISA for all 61 scFv-Fc antibodies binding to diphtheria toxin (filled symbol, solid line) 
and CRM197 (non-toxic mutant; open symbol, dotted line) with BSA as negative control (line). Detected with 
goat α human Fc antibody HRP conjugate, visualized with TMB substrate and measured at 450 nm with 620 nm 
reference. Figure modified from PhD thesis84.
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of V-genes from naive antibody gene libraries57 with the exception VH4-34. This V-gene is rarely selected from 
phage display libraries (based on our in-house data from >3500 phage display selected and validated scFv) but is 
common in the natural human antibody repertoire58. This V-gene is also described as self-reactive to both carbo-
hydrate structures of human erythrocytes and commensal bacteria59. Interestingly, both of the best neutralizing 
antibodies directed to the R- domain (see below) have the VH4-34 V-gene.
Figure 5. Titration ELISA for 35 IgG antibodies binding to diphtheria toxin (filled symbol, solid line) and 
CRM197 (non-toxic mutant; open symbol, dotted line) with BSA as negative control (line). Detected with goat 
α human Fc antibody HRP conjugate, visualized with TMB substrate and measured at 450 nm with 620 nm 
reference. Figure modified from PhD thesis84.
Figure 6. Cell based neutralization assay for 35 IgG antibodies using a toxin dose level of 4 × MCD. Untreated 
Vero cells are given as green dotted line. The threshold for neutralization is given as red dotted line (50% of 
untreated Vero cells). Figure modified from PhD thesis84.
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The binding of the neutralizing antibodies to DT and the mutant CRM19748,49 was analyzed and reduced 
binding to CRM197 was seen for many of the selected antibodies. This result is in accordance with Bigio et al.60 
who found, that the conformation of CRM197, which has only one amino acid change in the catalytic center, is 
not identical to wildtype DT. The antibodies were initially analyzed in the scFv-Fc format because the conversion 
from scFv to scFv-Fc is only one cloning step61. For further in vitro and in vivo assays, 35 selected antibodies were 
converted to the IgG format because IgGs are the preferred format for therapeutic antibodies54. Here, differences 
in the EC50 between the scFv-Fc format and IgG were measured. A few antibodies lost affinity by cloning from 
scFv to IgG format, possibly due to different folding or the reduced flexibility of the angle between VH and VL in 
the Fab/IgG compared to the scFv format because of the stabilization by CH1+ CL37,62,63. Conversely, the affinity 
was improved for the antibody ewe192-D8 whose initially weak EC50 increased by around 10-fold following 
conversion to IgG. The EC50 values determined by MST differed to that measured in ELISA by a factor of ~100. 
In ELISA the analyzed antibodies had an EC50 value of under 1 nM. The interaction in ELISA is measured on 
immobilized DT and not in solution which likely explains the vast difference to the MST results.
The recognized domains and minimal epitope regions of the neutralizing antibodies were determined by 
immunoblot or phage display. Epitope mapping by phage display64–66 is a good supplement to peptide arrays 
like PepSpots67,68 or microarrays69. While peptide arrays identify linear epitopes very precisely, conformational 
or non-continuous MERs can be identified by phage display. Using both approaches, the binding domain was 
identified for 33 antibodies, but it was not possible to identify the epitope domain for one of the antibodies. It 
was possible to narrow down the minimal epitope region (MER) to 14 amino acids in the best case. For two of 
the analyzed antibodies, the complete C-domain was selected by phage display, indicating that the epitope is not 
linear. Interestingly, these two antibodies bound the C-domain in western blot after SDS-PAGE, indicating suffi-
cient refolding of the C-domain on the PVDF membrane. In the case of ewe192-H8, domain mapping revealed 
that only the B-fragment was the antibody target and not a specific domain within that fragment of DT. However, 
using the phage display approach the T-domain of the B-fragment was identified showing that the conformation 
of the recognized MER may depend on the formation of T- and R-domains. It was demonstrated that all three 
DT domains are targets of highly neutralizing recombinant antibodies which is in accordance with previous 
publications showing that neutralizing human recombinant antibodies70,71 or murine monoclonal antibodies72 
can target all three domains.
The neutralization efficacy of the scFv-Fcs and IgGs were first analyzed in vitro using the Vero cell toxin 
neutralization assay. Approximately a third of the IgGs showed an improved in vitro efficacy (MED50%) com-
pared to the corresponding scFv-Fc. To our knowledge, this is the first direct comparison of scFv-Fc and IgG in 
in vitro neutralization assays. Other publications have only compared monovalent scFv with the corresponding 
bivalent IgG, e.g. for neutralization of varicella-zoster virus73. The anti R-domain antibodies, ewe372-H1-W and 
ewe375-D4 had an estimated relative potency of 454 IU/mg and 446 IU/mg, respectively, at 4 × MCD. The human 
recombinant antibodies developed elsewhere (315C470 and DTD471) were reported to have a lower potency (136 
IU/mg and 52 IU/mg, respectively). The in vitro neutralization assay using 315C4 of Sevigny et al.70 was also 
performed at a relatively low toxin dose level of ~4 × MCD (based on the end point quoted for the reference 
antitoxin), and the DT neutralization efficacy for DTD4 by Kakita et al.71 cannot be calculated in IU/mg from the 
data given in the publication.
The specific activity of the best neutralizing human monoclonal antibodies from our studies in the Vero cell 
TNT also exceeded (approximately 10-fold) the potency of a rat monoclonal antibody that was included in our 
study. To our knowledge, ewe372-H1-W and ewe375-D4 are the antibodies with the highest published in vitro 
DT neutralization potency.
For the in vivo neutralization experiments, a non-lethal intradermal challenge experiment51,52 was performed 
based on the method described in the European Pharmacopoeia. This assay is performed at a higher toxin dose 
Figure 7. Neutralization potency of IgG antibodies expressed as IU/mg determined by Vero cell neutralization 
assay with a toxin dose level of 4 × MCD. All IgGs analyzed are colour coded corresponding to their DT 
binding domain (red = C-domain, green = R-domain, blue = T-domain, green/blue-striped = B-fragment, 
yellow = unknown domain). The rat hybridoma antibody DT05 and corresponding recombinant IgG rDT05 
are represented in grey (and also targets the R-domain). The equine diphtheria anti toxin serum (DAT) is 
represented in black.
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(referred to as Lr/100) than that used in the routine Vero cell TNT. Surprisingly, we found that individual anti-
bodies did not neutralize DT even when the antibody dose was increased. In this assay, the specific activity was at 
least 500-fold lower compared to that measured in the Vero cell TNT at 4 × MCD. These findings were confirmed 
by performing the Vero cell TNT at higher toxin dose levels. An equine polyclonal DAT included as a comparator 
in all Vero cell TNT assays had a similar neutralizing potency at all toxin dose levels used. When the monoclonal 
antibodies were tested in combination – either as a pair or a trio - excellent neutralization of DT was observed 
in vivo (at Lr/100) and in vitro (at Lcd/100 and Lcd/10). The specific activity of the antibody combinations was 
#
Name antibody 
clone
Domain mapping
by immunoblot
Phage display
DT region 
(aa position) MER (minimal epitope region)
Domain according 
to MER
1 ewe191-A7 C-domain 98–128 NAETIKKELGLSLTEPLMEQVGTEEFIKRFG C-domain
2 ewe191-A9 C-domain — inconclusive —
3 ewe191-C1 C-domain — inconclusive —
4 ewe191-C10 n.d. — not analyzed —
5 ewe191-C11 C-domain 96–124 NAETIKKELGLSLTEPLMEQVGTEEFIKR C-domain
6 ewe191-C12 R-domain — inconclusive —
7 ewe191-D1 C-domain 98–130 NAETIKKELGLSLTEPLMEQVGTEEFIKRFGDG C-domain
9 ewe191-H10 C-domain 98–130 NAETIKKELGLSLTEPLMEQVGTEEFIKRFGDG C-domain
10 ewe191-H8 C-domain — inconclusive —
11 ewe192-A6 B-fragment — inconclusive —
12 ewe192-B5(P) R-domain — inconclusive —
13 ewe192-C11 C-domain — inconclusive —
14 ewe192-D7 C-domain 99–130 AETIKKELGLSLTEPLMEQVGTEEFIKRFGDG C-domain
15 ewe192-D8 n.d. 210–223 DVIRDKTKTKIESL T-domain
16 ewe192-E4 B-fragment — inconclusive —
17 ewe192-F11 n.d. — inconclusive —
18 ewe192-F6 B-fragment — inconclusive —
19 ewe192-G12 n.d. 194–230 SVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKM T-domain
20 ewe192-H11 C-domain — inconclusive —
21 ewe192-H7 C-domain 99–127 AETIKKELGLSLTEPLMEQVGTEEFIKRF C-domain
22 ewe192-H8 B-fragment 177–210 SVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIK T-domain
25 ewe371-B12 C-domain 99–123 AETIKKELGLSLTEPLMEQVGTEEF C-domain
36 ewe372-A12 C-domain — no binding phage particles in screening ELISA —
37 ewe372-A8 R-domain 436–471 TIPGKLDVNKSKTHISVNGRKIRMRCRAIDGDVTFC R-domain
39 ewe372-C10-W R-domain — no binding phage particles in screening ELISA —
40 ewe372-C4 R-domain 457–473 IRMRCRAIDGDVTFCRP R-domain
41 ewe372-C5 R-domain 436–473 TIPGKLDVNKSKTHISVNGRKIRMRCRAIDGDVTFCRP R-domain
43 ewe 372-D11 C-domain 1–146
GADDVVDSSKSFVMENFSSYHGTKPGYVD
SIQKGIQKPKSGTQGNYDDDWKGFYSTDN
KYDAAGYSVDNENPLSGKAGGVVKVTYPG
LTKVLALKVDNAETIKKELGLSLTEPLMEQV
GTEEFIKRFGDGASRVVLSLPFAEGSSS
C-domain
47 ewe372-D7 R-domain 437–472 IPGKLDVNKSKTHISVNGRKIRMRCRAIDGDVTFCR R-domain
49 ewe372-F3 R-domain — inconclusive —
50 ewe372-F6 T-domain — inconclusive —
52 ewe372-H1-S R-domain 378–403 PAYSPGHKTQPFLHDGYAVSWNTVED R-domain
53 ewe372-H1-W R-domain 383–401 GHKTQPFLHDGYAVSWNTV R-domain
59 ewe375-D4 R-domain 371–394 PAYSPGHKTQPFLHDGYAVSWNTV R-domain
61 ewe375-H4 C-domain 1–162
GADDVVDSSKSFVMENFSSYHGTKPGYVDS
IQKGIQKPKSGTQGNYDDDWKGFYSTDNKY
DAAGYSVDNENPLSGKAGGVVKVTYPGLTK
VLALKVDNAETIKKELGLSLTEPLMEQVGTEE
FIKRFGDGASRVVLSLPFAEGSSSVEYINNW
EQAKALSVE
C-domain
Table 4. Analysis of the bound domains and minimal epitope region (MER) for 35 neutralizing DT antibodies. 
The domain mapping was performed by SDS-PAGE, followed by western blot and immunostaining with the 
neutralizing antibody. The MERs were defined by selection of DT single gene phage display libraries on the 
neutralizing antibodies followed by DNA sequencing of the selected DT fragment phage particles. The domain 
mapping data was generated in a PhD thesis84.
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determined to be approximately 80 IU/mg in vivo and 80–160 IU/mg in vitro. At the low toxin dose level of 
4 × MCD in Vero cells, we did not observe any synergistic effect of combining more than one antibody. We 
hypothesize that the mode of action is not only based on neutralization, but also on the formation of aggregates 
as described by Heidelberger and Kendall74. This mode of action was also described for other recombinant anti-
bodies which bind more than one epitope on the targeted toxin, e.g. for the anti-TcdA antibody Actotoxumab 
binding to a repeating epitope structure on the toxin75 or bispecific VHH antibody constructs against the plant 
toxin ricin76,77. For the antibody 315C4 an in vivo neutralization potency using a lethal guinea pig challenge 
Figure 8. Overview of the identified minimal epitope regions (MERs) for 19 antibodies analyzed using single 
gene phage display. A) schematic overview and B) 3D based on pdb 1ddt, the MERs are highlighted. The 
antibody number is represented as shown in Table 4.
Antibody clone
scFv-Fc EC50 
[nM]
IgG EC50 
[nM}
Secondary binding
event
ewe191-A7 19.7 +/− 2.6 9.4 +/− 2.2 yes
ewe191-C12 3.1 +/− 0.6 10.7 +/− 2.2 yes
ewe192-B5(P) 40.5 +/− 1.8 12.8 +/− 1.1 no
ewe372-F6 6.8 +/− 2.6 11.5 +/− 1.1 yes
ewe375-D4 22.8 +/− 7.1 12.6 +/− 1.2 no
ewe375-H4 6.4 +/− 0.9 13.6 +/− 1.5 yes*
Table 5. Affinity measurement for selected anti-DT antibodies in scFv-Fc and IgG format. All measurements 
were performed in triplicate in PBS. *Here the secondary binding event was not as prominent.
Name antibody clone
4 × MCD
[IU/mg]
Lcd/1000
[IU/mg]
Lcd/100
[IU/mg]
Lcd/10 
[IU/mg]
ewe375-D4 (anti R-Domain) 445.7 446 <20 <2.8
ewe375-H4 (anti C-Domain) 40.5 41 <20 <3.2
ewe372-F6 (anti T-domain) 4.4 n.d. <20 <3.1
ewe375-D4 + ewe375-H4 n.d. n.d. 160 100
ewe375-D4 + ewe372-F6 n.d. n.d. 160 100
ewe375-H4 + ewe372-F6 n.d. n.d. 80 100
ewe375-D4 + ewe375-H4 + ewe372-F6 n.d. n.d 80 100
Table 6. In vitro neutralization at different toxin dose levels for individual antibodies and antibody 
combinations in the Vero cell TNT assay. The neutralization potency is reported as IU/mg. The assay using 
4xMCD DT is an independent experiment from the assay in Table 2. n.d. = not done.
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assay of 64 IU/mg was published70. Further in vivo tests were performed for the antibody S315 which is derived 
from 315C4, resulting in a neutralization potency which corresponds to 58.8 IU/mg78. An in vivo neutralization 
potency of 73.6 IU/mg were published by Kakita et al.71 for DTD4 using a rabbit skin test as in vivo model. Despite 
differences in the models used, our results suggest that the neutralizing potency of the antibody combinations 
tested in our study is comparable and likely superior to the results obtained for single monoclonal antibodies 
developed elsewhere.
The use of antibody combinations for the development of a therapeutic product is more challenging from a 
regulatory aspect, but may have clear advantages as a therapeutic because it mimics a polyclonal serum by binding 
to different epitopes. Further, the use of an antibody combination binding more than one domain on the target 
toxin may be a more robust therapeutic approach and may provide protection against toxin escape mutants. The 
antibodies described here are promising candidates for future regulatory and clinical development as an alterna-
tive to equine DAT for diphtheria therapy.
Material and Methods
Generation of an immune anti-DT antibody gene library.  For the generation of a human immune 
library against DT, blood from three donors who have been regularly boost-vaccinated was collected 7 days after 
they received a boost vaccination of a combined diphtheria and tetanus vaccine. This was performed in accordance 
with the Declaration of Helsinki. All the voluntary donors were informed about the project and gave their consent. 
The use of blood samples for the amplification of antibody gene fragments to develop antibody phage display 
libraries was approved by the ethical committee of the Technische Universität Braunschweig (Ethik-Kommission 
der Fakultät 2 der TU Braunschweig, approval number DM-2014-08). The donors have given their consent for 
study publication. The library construction was performed as described previously with minor modifications79. In 
brief, the peripheral blood mononuclear cells (PBMC) were extracted from the blood via Ficoll (GE Healthcare, 
Freiburg, Germany) and RNA isolated with Trizol and a Trizol RNA purification kit (Zymo Research, Freiburg, 
Germany). For the B-cell sorted library, B-cells were stained with mouse α-CD138 (FITC conjugated) antibody 
(ab27390, abcam, Cambridge, UK) and sorted via FACS and taken up in Trizol. In addition, the RNA of the sorted 
B cells was extracted using the Trizol RNA purification kit according to the manufacturer’s instructions. The RNA 
was converted into cDNA using Superscript III (Thermo Fisher Scientific, Waltham, USA) according to the man-
ufacturer’s instructions. The cDNA was amplified with specific primers for the VH chain, primers for kappa light 
chain and primer for lambda light chain. These PCR products were again amplified with primers adding a restric-
tion site for further cloning into the E. coli expression vector pHAL51. The vector pHAL51 is derived from the 
vector pHAL3057 with an AscI stuffer in the VL cloning site. Firstly, the light chain was cloned with the restriction 
sites MluI and NotI, and secondly the VH chain was cloned with the restriction sites HindIII and NcoI. The effi-
ciency of library cloning was tested with a colony PCR and the rate of complete scFv were determined. The libraries 
were further packaged with Hyperphage45,46 followed by addition of glycerine (20% (v/v)) and storage at −80 °C.
Antibody selection in microtiter plate. The antibody selection was performed as described previously 
with modifications33. In brief, for the panning procedure, the antigen was immobilized on a Costar Highbinding 
96 well plate (Corning, New York, USA). 1 µg of DT (List Biological Laboratories, Campbell, USA) was diluted 
in PBS (137 mM NaCl; 1.76 mM KH2PO4 × 2 H2O) and coated in the wells at 4 °C overnight. Next, the wells were 
blocked with 350 µL 2% MBPST (2% (w/v) milk powder in PBS; 0.05% Tween20) for 1 h at RT and then washed 
3 times with PBST (PBS; 0.05% Tween20). Before adding the libraries to the coated wells, the libraries (5 × 1010 
phage particles) were preincubated with 2% MPBST on blocked wells for 1 h at RT. The libraries were transferred 
to the coated wells, incubated for 2 h at RT and washed 10 times. Bound phage was eluted with trypsin (10 µg/
mL) at 37 °C and 5 µL of eluate was used for titration. The remaining 145 µL was transferred to a 96 deep well 
plate (Greiner Bio-One, Frickenhausen, Germany) and incubated with 145 µL E. coli TG1 (OD600 = 0.5) firstly 
for 30 min at 37 °C, then 30 min at 37 °C and 650 rpm to infect the phage particles. 1 mL 2xYT-GA (1.6% (w/v) 
Tryptone; 1% (w/v) Yeast extract; 0.5% (w/v) NaCl (pH 7.0), 100 mM D-Glucose, 100 µg/mL ampicillin) was 
added and incubated for 1 h at 37 °C and 650 rpm, followed by addition of 1 × 1010 cfu M13KO7 helper phage. 
Subsequently, the infected bacteria were incubated for 30 min at 37 °C followed by 30 min at 37 °C and 650 rpm 
before centrifugation for 10 min at 3220 × g. The supernatant was discarded and the pellet resuspended in fresh 
2xYT-AK (1.6% (w/v) Tryptone; 1% (w/v) Yeast extract; 0.5% (w/v) NaCl (pH 7.0), 100 µg/mL ampicillin, 50 µg/
mL kanamycin). The phage antibodies were amplified overnight at 30 °C and 650 rpm and used for the next 
panning round. In total three panning rounds were performed. In each round, the stringency of the washing 
Name antibody clone [IU/mg]
ewe375-D4 (anti R-domain) <0.72
ewe375-H4 (anti C-domain) <6.4
ewe372-F6 (anti T-domain) <1.23
ewe375-D4 + ewe375-H4 79.4
ewe375-D4 + ewe372-F6 79.4
ewe375-H4 + ewe372-F6 79.4
ewe375-D4 + ewe375-H4 + ewe372-F6 79.4
Table 7. In vivo neutralization (at Lr/100 toxin dose level) for individual antibodies and antibody combinations 
in the guinea pig intradermal challenge assay. The neutralization potency is reported as IU/mg.
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procedures was increased (20x in panning round 2 and 30x in panning round 3). After the third panning round, 
the titer plate was used to select monoclonal antibody clones for the screening ELISA.
production of soluble antibodies in Mtps and screening eLiSA. Soluble antibody fragments (scFv) 
were produced in 96-well MTPs with polypropylene (U96 PP, Greiner Bio-One). Briefly, 150 μL 2xYT-GA was 
inoculated with the bacteria bearing scFv expressing phagemids. MTPs were incubated overnight at 37 °C 
and 850 rpm in a MTP shaker (Thermoshaker PST-60HL-4, Lab4You, Berlin, Germany). A volume of 140 μL 
2xYT-GA in a PP-MTP well was inoculated with 10 μL of the overnight culture and grown at 37 °C and 850 rpm 
until bacteria reached an OD600 of 0.5. Bacteria were harvested by centrifugation for 10 min at 3,220 × g and the 
supernatant was discarded. To induce expression of the antibody genes, the pellets were resuspended in 150 μL 
2xYT supplemented with 100 μg/mL ampicillin and 50 μM isopropyl-beta D thiogalacto pyranoside (IPTG) and 
incubated at 30 °C and 850 rpm overnight. Bacteria were pelleted by centrifugation for 10 min at 3,220 × g and 
4 °C. The scFv-containing supernatant was transferred to a new PP-MTP and stored at 4 °C before ELISA analysis.
For the ELISA, 100 ng of DT was coated on 96 well microtitre plates (MaxiSorp, Thermo Fisher Scientific) 
in PBS (pH 7.4) overnight at 4 °C. After coating, the wells were washed three times with PBST and blocked with 
2% MPBST for 1 h at RT, followed by three washing steps with PBST. Supernatants containing monoclonal scFv 
were mixed with 2% MPBST (1:2) and incubated in the antigen coated plates for 1.5 h at RT followed by three 
PBST washing cycles. Bound scFv were detected using murine mAb 9E10 which recognizes the C-terminal c-myc 
tag (1:50 diluted in 2% MPBST) and a goat anti-mouse serum conjugated with horseradish peroxidase (HRP) 
(A0168, Sigma) (1:50,000 dilution in 2% MPBST). Bound antibodies were visualized with tetramethylbenzidine 
(TMB) substrate (20 parts TMB solution A (30 mM Potassium citrate; 1% (w/v) Citric acid (pH 4.1)) and 1 part 
TMB solution B (10 mM TMB; 10% (v/v) Acetone; 90% (v/v) Ethanol; 80 mM H2O2 (30%)) were mixed). After 
stopping the reaction by addition of 1 N H2SO4, absorbance at 450 nm with a 620 nm reference was measured in 
an ELISA plate reader (Epoch, BioTek, Bad Friedrichshall, Germany). Monoclonal binders were sequenced and 
analyzed using VBASE2 (www.vbase2.org)80.
Antibody selection in solution. For the panning in solution, the antigen was biotinylated with a biotin 
labelling reagent (EZ Link Sulfo-NHS-LC-Biotin, Thermo Fisher Scientific). 100 ng of the biotinylated antigen 
was preincubated in a 1.5 mL low protein binding tube (Eppendorf, Hamburg, Germany) with 2% BSA-PBS on an 
overhead shaker. After 2 h, 10 µL magnetic streptavidin beads (Dynabeads M-280, Thermo Fisher Scientific) were 
added to the tube and incubated for an additional 30 min. The tubes were placed for 5 min on a magnetic rack and 
the supernatant was discarded. The streptavidin beads were washed 10 times with 0.8 mL PBST. Bound phage was 
eluted with trypsin (10 µg/mL) at 37 °C and 5 µL was used for titration. The remaining 145 µL was transferred to 
a 96-well deep well plate and incubated with 145 µL E. coli TG1 (OD600 = 0.5) firstly for 30 min at 37 °C, then for 
30 min at 37 °C and 650 rpm to infect the phage particles. 1 mL 2xYT-GA was added and incubated for 1 h at 37 °C 
at 650 rpm followed by addition of 1 × 1010 M13KO7 helper phage. Again, the infected bacteria were incubated for 
30 min at 37 °C and 30 min at 37 °C and 650 rpm before a centrifugation for 10 min at 3220 × g. The supernatant 
was discarded and the pellet resuspended in fresh 2xYT-AK. The phage antibodies were amplified at 30 °C over-
night and 650 rpm and the produced phage particles were used for the next panning round. In total three panning 
rounds were performed. In each round, the stringency of the washing procedures was increased (20x in panning 
round 2 and 30x in panning round 3). The output of the third panning rounds was used for batch cloning into the 
scFv-Fc format and functional screening.
scFv-Fc and IgG antibody cloning, expression and purification.  Unique scFv sequences isolated by 
antibody-phage display in MTPs or the complete output of the third panning rounds (all scFv encoding DNA 
fragments) were subcloned into pCSE2.7-hIgG1-Fc-XP using NcoI/NotI (New England Biolabs, Frankfurt, 
Germany) for mammalian production as scFv-Fc, an IgG-like antibody format. The vector pCSE2.7-hIgG1-Fc-XP 
is derived from the vector pCSE2.6-hIG1-Fc-XP61 with an additional AscI restriction site in the cloning site 
for improved NcoI/NotI cloning. The best neutralizing antibodies were converted into the human IgG1 format 
by subcloning of VH in the vector pCSEH1c (heavy chain) and VL in the vector pCSL3l/pCSL3k (light chain 
lambda/kappa)37. EXPI293F (Thermo Fisher Scientific) cells were transfected with both vectors in parallel. For 
production, the transfected EXPI293F cells were cultured in chemically defined medium F17 (Thermo Fisher 
Scientific) supplemented with 0.1% pluronic F68 (PAN-Biotech, Aidenbach, Germany) and 7.5 mM L-glutamine 
(Merck). A subsequent protein A purification was performed as described previously61.
Antibody titration eLiSA. The titration ELISA was performed similar to the indirect antigen ELISA (see 
above). A dilution series was made in blocking solution starting with 1 µg antibody. Afterwards, 100 µL of each 
dilution was added per well and incubated for 1 h at RT. The plate was washed 3 times with PBST. Goat α-human 
IgG (Fc-specific, A0170, Sigma) conjugated to horse radish peroxidase (HRP, 1:70,000) was used as the secondary 
detection antibody and was incubated for 1 h at RT. Unbound antibodies were removed by additional washing 
steps. Bound antibodies were visualized with TMB substrate (20 parts TMB solution A and 1 part TMB solution 
B). After stopping the reaction by adding 100 µL 1 N H2SO4, absorbance at 450 nm with a 620 nm reference was 
measured in an ELISA plate reader.
pipe cloning. Polymerase incomplete primer extension (PIPE) cloning was used to introduce a site directed 
mutagenesis followed by cloning into the pCSE2.7-hIgG1-XP vector. PCR was performed in 10 µL reactions using 
0.5 ng of template, 0.25 µM forward and reverse primers, Q5 reaction buffer and 1 U HotStart Q5 DNA polymerase 
(NEB). The cycling conditions were: 98 °C 30 sec, 30 × (98 °C 10 s, 72 °C 2:30 min for products >1.5 kb or 1 min 
for < 1.5 kb). The correct size of the PCR products was checked with a 1% (w/v) agarose gel in TAE buffer containing 
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1 µg ethidium bromide. 2.5 µL vector product and 2.5 µL insert product were digested for 1 h at 37 °C with 10 U of 
DpnI NEB and the total amount was used to transform 20 µL of XL1 Blue MRF’ supercompetent cells (Agilent 
Technologies, Waldbronn, Germany) via heat shock transformation according to manufacturer’s instructions.
Recombinant production and purification of DT fragments and domains.  The gene fragments 
encoding the A or B fragment of DT or the single domains, were amplified from Corynebacterium diphtheria 
(DSM 43989, DSMZ) and cloned into pET21a(+) (Merck). Production of the recombinant proteins with a 
C-terminally 6 × His-tagged proteins in the E. coli BLR(DE3) expression system was performed in LB-A-IPTG 
(1% (w/v) tryptone; 0.5% (w/v) yeast extract; 1% (w/v) NaCl (pH 7.0), 100 µg/mL ampicillin, 0.5 mM IPTG) over 
3 h at 37 °C. Recombinant proteins containing a HIS-tag were purified using immobilized metal ion affinity chro-
matography (IMAC). The bacterial culture was centrifuged at 10,000 × g for 15 min at 4 °C. The pellet was then 
resuspended in binding buffer (20 mM Tris-HCl, 0.5 M NaCl, 5 mM imidazole, and, if the protein was not soluble, 
6 M urea was added) and sonicated 3 times for 2 min with pulsed cycles. Afterwards, the suspension was centri-
fuged at 16,000 × g for 10 min at 4 °C and the supernatant was loaded to a support column containing Sepharose 
(activated with 0.1 M NiSO4). The column was washed with washing buffer (20 mM Tris-HCl, 0.5 M NaCl, 60 mM 
imidazole, for some domains 6 M urea was added) until a OD280 of approximately 0 for the flow-through was 
reached. The bound antibodies were then eluted with elution buffer (20 mM Tris-HCl, 0.5 M NaCl, 1 M imidazole, 
for some domains 6 M urea was added). The buffer was exchanged to PBS by dialysis and the purified proteins 
were stored for a short time at 4 °C or aliquoted and stored at −20 °C long term.
cultivation of vero cells and vero cell toxin neutralization test. For in vitro DT Toxin neutralization 
assay (TNT), a Vero cell line (African green monkey kidney cells) was used. Vero cells were cultivated in EMEM 
medium (Biochrom) supplemented with 0.015 M HEPES (Carl Roth), 0.1% Glucose (Carl Roth), 100 µg/mL pen-
icillin/streptomycin (Biochrom), 2 mM l-glutamine (Biochrom) and 5% fetal calf serum (Biochrom) at 37 °C and 
5% (v/v) CO2, and passaged 2–3 times per week when confluency exceeded 90%.
For routine screening, the Vero cell assay was performed using a DT dose referred to as 4 × MCD. This is a 
fixed dose of DT at 4 × the minimum concentration causing more than 50% cytopathic effect in Vero cells. This 
is the most sensitive version of the assay allowing very low concentrations of antibodies to be screened for neu-
tralization. For further analysis of IgG antibodies, assays were performed at higher toxin dose levels referred to as 
Lcd/1000, Lcd/100 or Lcd/1081. These DT dose levels are defined as the minimum concentration of DT required 
to produce a cytopathic effect in Vero cells after 6 days in culture when DT is mixed with a fixed concentration 
of a reference antitoxin at 0.1, 0.01 or 0.001 IU/ml for Lcd/10, Lcd/100 or Lcd/1000, respectively. The DT dose 
levels were pre-determined by titration of DT against the reference antitoxin (WHO International Standard for 
Diphtheria Antitoxin Equine, NIBSC code 17/230).
For the neutralization assays, serial, two-fold dilutions of antibody samples either individually (ranging from 
300 µg to 0.1 pg) or in combination were made in complete EMEM in 96-well tissue culture plates, prior to addi-
tion of an equal volume (50 µL) of diphtheria toxin (TU Braunschweig: List Biological Laboratories; NIBSC: 
EDQM Biological Reference Preparation, batch 1) at a fixed concentration (dependent on the DT dose level of 
the assay). Samples were left for 1 h at room temperature to allow DT neutralization to occur followed by addition 
of 50 µL of a suspension of Vero cells to give a cell density of 2 × 104 cells per well. Control wells were included 
on every plate containing DT only (toxin control) or cells only (cell control). The reference DAT antitoxin was 
included on every plate. Plates were incubated for 6 days at + 37 °C in humidified air supplemented with 5% 
CO2. Cell viability was then determined by incubating cells with Thiazolyl Blue Tetrazolium Bromide (MTT, 
Sigma). Cells were incubated with MTT (5 mg/ml in PBS) for 4 h at + 37 °C in humidified air containing 5% CO2. 
Supernatants were carefully removed and the MTT-formazan product in viable cells was extracted using 10% w/v 
SDS in 50% v/v dimethylformamide, pH 4.7 (100 µL/well). The plates were returned to the incubator overnight to 
allow for complete extraction and stabilization of the coloured product and the absorbance was read at 570 nm. 
End points were defined as the lowest dilution at which neutralization of DT was sufficient to produce >50% 
viable Vero cells (where the 50% cut-off was based on the half-maximum OD for eight control wells containing 
Vero cells only and eight wells using the specific, constant DT concentration).
Domain mapping by immuno blot. Sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) was used to separate the DT-fragments according to their electrophoretic mobility. The 
DT-fragments were mixed with 5 × Laemmli’s sample buffer and were boiled for 10 min at 95 °C. A protein stand-
ard and the samples were then loaded onto the gel. Electrophoresis was performed at 200 V and 400 mA per gel 
for 45 min followed by western blot analysis.
A semi-dry western blot was performed to transfer DT-fragments from SDS gels onto polyvinylidene fluo-
ride (PVDF) membranes (Bio-Rad, Feldkirchen, Germany) at 20 V for 30 min. After western blotting, the mem-
brane was blocked with M-PBST for 60 min at room temperature. Detection of DT-fragments was performed 
indirectly via developed DT-neutralizing human antibodies followed by Fcγ specific AP-conjugated secondary 
antibody (109-055-098, Jackson Immuno Research Laboratories, Cambridgeshire, UK) in a 1:20,000 dilution in 
MPBST. After 1 h incubation at room temperature, the membrane was washed with PBST and AP-substrate buffer 
(100 mM Tris HCl pH 9.5, 0.5 mM MgCl2) and bound antibodies were visualized with nitro blue tetrazolium 
chloride (0.30 mg/mL) and 5-Bromo-4-chloro- 3-indolyl phosphate (0.15 mg/mL) in AP substrate buffer. Finally, 
the membrane was washed with water and dried. For documentation, the blots were scanned.
epitope mapping by phage display. For epitope mapping, single gene libraries were constructed as 
described previously64. In brief, the DT encoding DNA was fragmented by sonication, polished and blunt end 
cloned into the digested pHORF3 vector50,82. For transformation, electro-competent E. coli cells SS320 (Lucigen, 
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Middleton, USA) were used. The efficiency of cloning was tested with a colony PCR and the rate of complete frag-
ments were determined. The libraries were further packaged with Hyperphage45,46. The produced phage particles 
were stored at −80 °C after adding glycerine (20% (v/v)).
The panning in solution for epitope mapping was performed as described previously69. In brief, 1 µg of an 
unrelated antibody (negative control) was coated in 100 µL PBS overnight at 4 °C in a cavity of a Costar High 
Binding microtiter plate. The wells were then blocked with panning block for 1 h at RT and then washed 3x with 
PBST using a microplate washer. Next, 109 cfu of the DT-fragment-phage library was diluted in 150 µL 2% (w/v) 
BSA in PBST, added to the negative control well, and incubated for 1 h at room temperature. Protein A cou-
pled magnetic beads (SureBeads, BioRad) were prepared according to manufacturer’s instructions. Preincubated 
phage was transferred to a protein low binding (PLB) microtube (Sarstedt) and co-incubated with 15 µL Protein A 
beads for 1 h on a programmable rotator-mixer (PRM) (PTR-30 Grantbio) to further remove sticky or unspecific 
phage. The magnetic beads were then removed with a magnetic rack and discarded. 100 ng of the DT neutralizing 
antibody was added to the remaining phage and incubated for 2 h on a rotator-mixer. 15 µL of freshly prepared 
magnetic protein A beads were added and incubated for another 30 minutes followed by a separation of the 
beads on a magnetic rack. The supernatant was discarded and the beads were washed 10x with 1 mL PBST and 
then eluted with 150 µL trypsin (10 µg/mL) and incubated at 37°C for 30 min. The identification of MERs was 
performed by ELISA. In brief, for the screening ELISA, 100 ng of antibody was coated on 96 well microtitre plates 
(MaxiSorp, Thermo Fisher Scientific) in PBS pH 7.4 overnight at 4°C. Following coating, the wells were washed 
with PBST and blocked with 2% MPBST for 1 h at RT, followed by three washing steps with PBST. Supernatant 
containing DT-fragment bearing phage were mixed with 2% MPBST (1:4) and incubated in the antibody coated 
plates for 90–120 min at RT followed by three PBST washing cycles. Bound phage was detected using HRP conju-
gated mouse anti-M13 antibody (27-9421-01, GE Healthcare) diluted 1:40,000 in 2% MPBST and visualized with 
TMB substrate (20 parts TMB solution A and 1 part TMB solution B). After stopping the reaction by addition 
of 1 N H2SO4, absorbance at 450 nm with a 620 nm reference was measured in an ELISA plate reader (Epoch, 
BioTek). The phagemids encoding the Bound DT-fragments were sequenced and aligned to the DT sequence to 
identify the MER.
Microscale thermophoresis for affinity determination.  DT was labelled in PBS pH 7.4 using the 
Amine Reactive Monolith Protein Labeling Kit RED-NHS 2nd Generation (NanoTemper, Munich, Germany) 
following the manufacturer’s protocol. In total, 5 nM of labelled DT was premixed in a 384 well non-binding pol-
ystyrene plate (Corning) with 12 different concentrations (1:2 dilution) of the respective antibody or scFv-Fc in 
PBS by Precision XS (BioTek Instruments). For Microscale Thermophoresis (MST) measurements with Monolith 
NT. Automated (NanoTemper) in Monolith NT. Automated Capillary Chips (NanoTemper), an excitation power 
of 20% and a high MST power of 60% was applied. The Hill coefficient was determined by MO Affinity Analysis 
software (NanoTemper) for the IgGs after 10 sec of heating and for the scFv-Fc after 15 sec of heating to gain suffi-
cient amplitude signals. All measurements were performed in triplicate resulting in signal to noise ratios over 15.
In vivo efficacy of IgGs by intradermal challenge in guinea pigs.  Potency of IgGs by intradermal 
challenge was performed at NIBSC. In vivo studies are regulated by the Animals (Scientific Procedures) Act 1986 
in accordance with EC Directive 2010/63/EU. Studies were reviewed and approved by the NIBSC Animal Welfare 
and Ethical Review Body and performed under a Project Licence granted by the UK Home Office. For the neu-
tralization assays, female guinea pigs (Dunkin Hartley strain) weighing between 350–450 g were obtained from 
B&K Universal (Marshall BioResources UK) Animals (up to 8 per pen) were housed in rectangular or square 
floor pens with a metal and perspex construction, above minimum size requirements defined by UK legislation. 
Animals had olfactory and visual stimulation between the pens with autoclaved dust-free wood shavings as bed-
ding (‘eco-pure’ supplied by Datesand). Husbandry conditions were a 12 h light, 12 h dark cycle, including ‘dawn 
and dusk’ half-light periods of 30 minutes each. Temperature was maintained between 16–23 degrees Celsius. A 
pelleted diet (‘FD1’ supplied by LBS), filtered mains water (bottle and bowl) and autoclaved hay were all provided 
ad libitum. Washed fresh greens were provided 3 times weekly. Environmental enrichment including plastic and/
or cardboard boxes, tunnels and shelters, and nesting material were also provided in each pen. Animals were 
health checked at least once per day as stock, and up to 3 times daily whilst on test by trained and competent 
technical staff, with attention to the size and degree of erythema at the injection sites and the general condition 
and behaviour of the animals.
The assay was performed according to the method described in the European Pharmacopoeia monograph for 
Diphtheria Antitoxin83. A series of 6 dilutions of antibody sample (either individually or as a combination) were 
mixed with a fixed volume of DT (EDQM Biological Reference Preparation, batch 1) at a DT dose level of Lr/100. 
The Lr/100 dose level for this toxin was pre-determined by titration against 0.01 IU/ml of a reference antitoxin 
(WHO International Standard for Diphtheria Antitoxin Equine, NIBSC code 17/230). A series of 6 dilutions of 
the reference antitoxin were also prepared and mixed with the same amount of DT in parallel to allow for deter-
mination of relative potency. Samples were allowed to stand at RT for 30–40 minutes prior to intradermal injec-
tion (0.2 mL) into the shaved flank of a guinea pig. A group of 2 animals was used for each antibody sample (or 
combination) or the reference antitoxin with 3 dilutions injected per flank. For each sample, the largest volume 
of antitoxin failing to protect guinea pigs from the local erythematous effect of DT was defined as the end point 
and potency was determined relative to the end point for the reference antitoxin, after taking into account total 
dilution factor for the sample.
Received: 3 October 2019; Accepted: 17 December 2019;
Published: xx xx xxxx
1 9Scientific RepoRtS |          (2020) 10:571  | https://doi.org/10.1038/s41598-019-57103-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
References
 1. Berkowitz, A. L. Tetanus, Botulism, and Diphtheria. Contin. (Minneap. Minn.) 24, 1459–1488 (2018).
 2. Moore, L. S. P. et al. Corynebacterium ulcerans cutaneous diphtheria. Lancet Infect. Dis. 15, 1100–1107 (2015).
 3. Hadfield, T. L., McEvoy, P., Polotsky, Y., Tzinserling, V. A. & Yakovlev, A. A. The pathology of diphtheria. J. Infect. Dis. 181(Suppl 1), 
S116–120 (2000).
 4. Kneen, R. et al. Penicillin vs. erythromycin in the treatment of diphtheria. Clin. Infect. Dis. 27, 845–850 (1998).
 5. Wagner, K. S. et al. A review of the international issues surrounding the availability and demand for diphtheria antitoxin for 
therapeutic use. Vaccine 28, 14–20 (2009).
 6. Hamborsky, J., Kroger, A. & Wolfe, S. Epidemiology and Prevention of Vaccine-Preventable Diseases. (Public He, 2015).
 7. Murphy, J. R. Corynebacterium Diphtheriae. In Medical Microbiology (ed. Baron, S.) (University of Texas Medical Branch at 
Galveston, 1996).
 8. Uchida, T., Gill, D. M. & Pappenheimer, A. M. Mutation in the structural gene for diphtheria toxin carried by temperate phage. Nat. 
N. Biol. 233, 8–11 (1971).
 9. Greenfield, L. et al. Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage beta. Proc. Natl. 
Acad. Sci. USA 80, 6853–6857 (1983).
 10. Smith, W. P., Tai, P. C., Murphy, J. R. & Davis, B. D. Precursor in cotranslational secretion of diphtheria toxin. J. Bacteriol. 141, 
184–189 (1980).
 11. Kaczorek, M. et al. Nucleotide sequence and expression of the diphtheria tox228 gene in Escherichia coli. Science 221, 855–858 
(1983).
 12. Gill, D. M. & Pappenheimer, A. M. Structure-activity relationships in diphtheria toxin. J. Biol. Chem. 246, 1492–1495 (1971).
 13. Collier, R. J. & Kandel, J. Structure and activity of diphtheria toxin. I. Thiol-dependent dissociation of a fraction of toxin into 
enzymically active and inactive fragments. J. Biol. Chem. 246, 1496–1503 (1971).
 14. Drazin, R., Kandel, J. & Collier, R. J. Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact 
toxin molecule. J. Biol. Chem. 246, 1504–1510 (1971).
 15. Choe, S. et al. The crystal structure of diphtheria toxin. Nature 357, 216–222 (1992).
 16. Dorland, R. B., Middlebrook, J. L. & Leppla, S. H. Receptor-mediated internalization and degradation of diphtheria toxin by monkey 
kidney cells. J. Biol. Chem. 254, 11337–11342 (1979).
 17. Morris, R. E., Gerstein, A. S., Bonventre, P. F. & Saelinger, C. B. Receptor-mediated entry of diphtheria toxin into monkey kidney 
(Vero) cells: electron microscopic evaluation. Infect. Immun. 50, 721–727 (1985).
 18. Moskaug, J. O., Sandvig, K. & Olsnes, S. Low pH-induced release of diphtheria toxin A-fragment in Vero cells. Biochemical evidence 
for transfer to the cytosol. J. Biol. Chem. 263, 2518–2525 (1988).
 19. Pappenheimer, A. M. Diphtheria toxin. Annu. Rev. Biochem. 46, 69–94 (1977).
 20. Komatsu, N., Oda, T. & Muramatsu, T. Involvement of both caspase-like proteases and serine proteases in apoptotic cell death 
induced by ricin, modeccin, diphtheria toxin, and pseudomonas toxin. J. Biochem. 124, 1038–1044 (1998).
 21. von Behring, E. & Kitasato, S. Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. 
Dtsch. Medizinische Wochenzeitschrift 16, 1113–1114 (1890).
 22. Grundy, J. & Biggs, B.-A. The Impact of Conflict on Immunisation Coverage in 16 Countries. Int. J. Health Policy Manag. 8, 211–221 
(2018).
 23. Dureab, F. et al. Diphtheria outbreak in Yemen: the impact of conflict on a fragile health system. Confl. Health 13, 19 (2019).
 24. Paniz-Mondolfi, A. E. et al. Resurgence of Vaccine-Preventable Diseases in Venezuela as a Regional Public Health Threat in the 
Americas. Emerg. Infect. Dis. 25, 625–632 (2019).
 25. Finger, F. et al. Real-time analysis of the diphtheria outbreak in forcibly displaced Myanmar nationals in Bangladesh. BMC Med. 17, 
58 (2019).
 26. Keith, J. R. The Treatment of Serum Sickness Occurring in Diphtheria. Br. Med. J. 2, 105 (1911).
 27. Tuft, L. & Ramsdell, S. G. The Antibody Response in the Human Being After Injection with Normal Horse Serum. J. Exp. Med. 50, 
431–437 (1929).
 28. Kniker, W. T. & Cochrane, C. G. The localization of circulating immune complexes in experimental serum sickness. The role of 
vasoactive amines and hydrodynamic forces. J. Exp. Med. 127, 119–136 (1968).
 29. Both, L., White, J., Mandal, S. & Efstratiou, A. Access to diphtheria antitoxin for therapy and diagnostics. Euro. Surveill. 19 (2014).
 30. Laustsen, A. H. How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases? 
Expert. Opin. Drug. Discov. 1–10, https://doi.org/10.1080/17460441.2019.1646723 (2019).
 31. Kuhn, P. et al. Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. 
Proteom. Clin. Appl. 10, 922–948 (2016).
 32. Frenzel, A., Schirrmann, T. & Hust, M. Phage display-derived human antibodies in clinical development and therapy. MAbs 8, 
1177–1194 (2016).
 33. Russo, G. et al. Parallelized Antibody Selection in Microtiter Plates. Methods Mol. Biol. 1701, 273–284 (2018).
 34. Ch’ng, A. C. W., Hamidon, N. H. B., Konthur, Z. & Lim, T. S. Magnetic Nanoparticle-Based Semi-Automated Panning for High-
Throughput Antibody Selection. Methods Mol. Biol. 1701, 301–319 (2018).
 35. Ledsgaard, L., Kilstrup, M., Karatt-Vellatt, A., McCafferty, J. & Laustsen, A. H. Basics of Antibody Phage Display Technology. Toxins. 
(Basel) 10 (2018).
 36. Schirrmann, T., Meyer, T., Schütte, M., Frenzel, A. & Hust, M. Phage display for the generation of antibodies for proteome research, 
diagnostics and therapy. Molecules 16, 412–426 (2011).
 37. Steinwand, M. et al. The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs 6, 204–218 
(2014).
 38. Bujak, E., Matasci, M., Neri, D. & Wulhfard, S. Reformatting of scFv antibodies into the scFv-Fc format and their downstream 
purification. Methods Mol. Biol. 1131, 315–334 (2014).
 39. Miethe, S. et al. Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B. PLoS One 11, 
e0161446 (2016).
 40. Miethe, S. et al. Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E. PLoS One 10, e0139905 (2015).
 41. Rasetti-Escargueil, C. et al. The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum 
Antibodies. Toxins. (Basel) 9 (2017).
 42. Pelat, T. et al. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol. 9, 60 
(2009).
 43. Pelat, T. et al. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor 
(LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob. Agents Chemother. 51, 2758–64 
(2007).
 44. Laustsen, A. H. et al. In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human 
IgG antibodies. Nat. Commun. 9, 3928 (2018).
 45. Soltes, G. et al. On the influence of vector design on antibody phage display. J. Biotechnol. 127, 626–37 (2007).
 46. Rondot, S., Koch, J., Breitling, F. & Dübel, S. A helper phage to improve single-chain antibody presentation in phage display. Nat. 
Biotechnol. 19, 75–8 (2001).
20Scientific RepoRtS |          (2020) 10:571  | https://doi.org/10.1038/s41598-019-57103-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
 47. Hoy, C. S. & Sesardic, D. In vitro assays for detection of diphtheria toxin. Toxicol. Vitro 8, 693–695 (1994).
 48. Metz, B., Jiskoot, W., Hennink, W. E., Crommelin, D. J. A. & Kersten, G. F. A. Physicochemical and immunochemical techniques 
predict the quality of diphtheria toxoid vaccines. Vaccine 22, 156–167 (2003).
 49. Proia, R. L., Hart, D. A., Holmes, R. K., Holmes, K. V. & Eidels, L. Immunoprecipitation and partial characterization of diphtheria 
toxin-binding glycoproteins from surface of guinea pig cells. Proc. Natl. Acad. Sci. USA 76, 685–689 (1979).
 50. Kügler, J. et al. Identification of immunogenic polypeptides from a Mycoplasma hyopneumoniae genome library by phage display. 
Appl. Microbiol. Biotechnol. 80, 447–58 (2008).
 51. Sesardic, D., Prior, C., Daas, A. & Buchheit, K. H., National Institute for Biological Standards and Control, Hertfordshire, UK 
European Directorate for the Quality of Medicines, Council of Europe, Strasbourg Cedex 1, France. Collaborative study for 
establishment of the European Pharmacopoeia BRP batch 1 for diphtheria toxin. Pharmeuropa Bio 2003, (5–21 (2003).
 52. Winsnes, R., Sesardic, D., Daas, A. & Behr-Gross, M.-E. Collaborative study for the validation of serological methods for potency 
testing of diphtheria toxoid vaccines-part 1. Pharmeuropa Bio 2003, 35–68 (2004).
 53. Frenzel, A. et al. Designing Human Antibodies by Phage Display. Transfus. Med. Hemother 44, 312–318 (2017).
 54. Strohl, W. R. Current progress in innovative engineered antibodies. Protein Cell 9, 86–120 (2018).
 55. Haurum, J. S. Recombinant polyclonal antibodies: the next generation of antibody therapeutics? Drug. Discov. Today 11, 655–660 
(2006).
 56. Schütte, M. et al. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of 
Aspergillus fumigatus. PLoS One 4, e6625 (2009).
 57. Kügler, J. et al. Generation and analysis of the improved human HAL9/10 antibody phage display libraries. BMC Biotechnol. 15, 10 
(2015).
 58. Tiller, T. et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical 
properties. MAbs 5, 445–470 (2013).
 59. Schickel, J.-N. et al. Self-reactive VH4-34-expressing IgG B cells recognize commensal bacteria. J. Exp. Med. 214, 1991–2003 (2017).
 60. Bigio, M. et al. Conformational changes in diphtheria toxoids. Analysis with monoclonal antibodies. FEBS Lett. 218, 271–276 
(1987).
 61. Jäger, V. et al. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC 
Biotechnol. 13, 52 (2013).
 62. Thie, H. et al. Rise and fall of an anti-MUC1 specific antibody. PLoS One 6, e15921 (2011).
 63. Lord, D. M. et al. Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody. MAbs 
10, 444–452 (2018).
 64. Fühner, V. et al. Epitope Mapping via Phage Display from Single-Gene Libraries. Methods Mol. Biol. 1904, 353–375 (2019).
 65. Moreira, G. M. S. G., Fühner, V. & Hust, M. Epitope Mapping by Phage Display. Methods Mol. Biol. 1701, 497–518 (2018).
 66. Rojas, G., Tundidor, Y. & Infante, Y. C. High throughput functional epitope mapping: revisiting phage display platform to scan target 
antigen surface. MAbs 6, 1368–1376 (2014).
 67. Li, R. et al. Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events 
in the N terminus. J. Mol. Biol. 301, 567–573 (2000).
 68. Russo, G. et al. Sequence defined antibodies improve the detection of cadherin 2 (N-cadherin) during zebrafish development. N. 
Biotechnol. 45, 98–112 (2018).
 69. Fühner, V. et al. Development of Neutralizing and Non-neutralizing Antibodies Targeting Known and Novel Epitopes of TcdB of 
Clostridioides difficile. Front. Microbiol. 9, 2908 (2018).
 70. Sevigny, L. M. et al. Identification of a human monoclonal antibody to replace equine diphtheria antitoxin for treatment of 
diphtheria intoxication. Infect. Immun. 81, 3992–4000 (2013).
 71. Kakita, M. et al. Isolation of a human monoclonal antibody with strong neutralizing activity against diphtheria toxin. Infect. Immun. 
74, 3682–3683 (2006).
 72. Danelli M das, G., Teixeira, L. M., Formiga, L. C. & Peralta, J. M. Protective monoclonal antibodies to diphtheria toxin. Mem. Inst. 
Oswaldo Cruz 86, 265–267 (1991).
 73. Kausmally, L. et al. Neutralizing human antibodies to varicella-zoster virus (VZV) derived from a VZV patient recombinant 
antibody library. J. Gen. Virol. 85, 3493–3500 (2004).
 74. Heidelberger, M. & Kendall, F. E. Quantitative studies on the precipitin reaction. J. Exp. Med. 555–561 (1932).
 75. Hernandez, L. D. et al. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab. 
J. Mol. Biol. 429, 1030–1044 (2017).
 76. Herrera, C., Klokk, T. I., Cole, R., Sandvig, K. & Mantis, N. J. A Bispecific Antibody Promotes Aggregation of Ricin Toxin on Cell 
Surfaces and Alters Dynamics of Toxin Internalization and Trafficking. PLoS One 11, e0156893 (2016).
 77. Herrera, C., Tremblay, J. M., Shoemaker, C. B. & Mantis, N. J. Mechanisms of Ricin Toxin Neutralization Revealed through 
Engineered Homodimeric and Heterodimeric Camelid Antibodies. J. Biol. Chem. 290, 27880–27889 (2015).
 78. Smith, H. L., Cheslock, P., Leney, M., Barton, B. & Molrine, D. C. Potency of a human monoclonal antibody to diphtheria toxin 
relative to equine diphtheria anti-toxin in a guinea pig intoxication model. Virulence 1–9, https://doi.org/10.1080/21505594.2016.1
171436 (2016).
 79. Kügler, J., Tomszak, F., Frenzel, A. & Hust, M. Construction of Human Immune and Naive scFv Libraries. Methods Mol. Biol. 1701, 
3–24 (2018).
 80. Mollova, S., Retter, I., Hust, M., Dübel, S. & Müller, W. Analysis of single chain antibody sequences using the VBASE2 Fab analysis 
tool. In Antibody Engineering 3–10 (Springer Verlag, 2010).
 81. Gupta, R. K., Higham, S., Gupta, C. K., Rost, B. & Siber, G. R. Suitability of the Vero cell method for titration of diphtheria antitoxin 
in the United States potency test for diphtheria toxoid. Biologicals 22, 65–72 (1994).
 82. Kügler, J., Zantow, J., Meyer, T. & Hust, M. Oligopeptide m13 phage display in pathogen research. Viruses 5, 2531–2545 (2013).
 83. Council of Europe. European Pharmacopoeia (Ph. Eur.) (2019).
 84. Wenzel, E. V. Development of recombinant human anti-diphtheria toxin neutralizing antibodies for diphtheria therapy (2019). PhD 
thesis Technische Universität Braunschweig.
 85. Bennett, M. J., Choe, S. & Eisenberg, D. Refined structure of dimeric diphtheria toxin at 2.0 A resolution. Protein Sci. 3, 1444–1463 
(1994).
Acknowledgements
We kindly acknowledge the financial support of the PETA International Science Consortium Ltd. for conducting 
the non-animal research components of this project to replace horse use and the Center for Contemporary 
Equine Studies.
2 1Scientific RepoRtS |          (2020) 10:571  | https://doi.org/10.1038/s41598-019-57103-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
Author contributions
E.V.W. designed and performed experiments, analyzed data and drafted the manuscript. M.B., R.T. and M.S. 
performed experiments and analyzed data. J.B., S.D. and A.E. participated in the design of the study and analyzed 
data. D.S. participated in the design of the study and conceived the study. P.S. performed experiments, conceived 
the study, participated in the design of the study, analyzed data and drafted the manuscript. M.H. conceived the 
study, participated in the design of the study, analyzed data and drafted the manuscript. All authors reviewed the 
final manuscript.
competing interests
The authors intend to file a patent on the described anti-diphtheria toxin antibodies.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-57103-5.
Correspondence and requests for materials should be addressed to M.H.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
